<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639999</url>
  </required_header>
  <id_info>
    <org_study_id>4-2020-1038</org_study_id>
    <nct_id>NCT04639999</nct_id>
  </id_info>
  <brief_title>Impact of MIgalastat TheRApy on CaRdiac Function in patiEnts With Fabry's Cardiomyopathy (MIRACRE-Fabry Trial)</brief_title>
  <official_title>Impact of MIgalastat TheRApy on CaRdiac Function in patiEnts With Fabry's Cardiomyopathy (MIRACRE-Fabry Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study. No treatment or intervention will be assigned to the&#xD;
      subjects. All patients will receive full standard of care concomitant medication for the&#xD;
      treatment of their cardiac condition. 20 patients with genetically confirmed Anderson-Fabry&#xD;
      disease who have a plan to start Migalastat will undergo 2D strain, diastolic stress&#xD;
      echocardiography, LV vortex flow analysis, and CMR at baseline and after 2 year of treatment&#xD;
      with Migalastat for follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Objectives - to evaluate the impact of chaperone therapy on LV diastolic function and&#xD;
           flow in patients with Fabry's cardiomyopathy using LV 2D strain, diastolic stress&#xD;
           echocardiography, LV vortex flow and CMR.&#xD;
&#xD;
        2. Primary/Secondary Endpoint&#xD;
&#xD;
           A. Primary endpoint:&#xD;
&#xD;
           - Change of peak exercise E/E' by diastolic stress echocardiography, global longitudinal&#xD;
           strain and LV vortex flow parameters at 2 year follow up.&#xD;
&#xD;
           B. Secondary endpoints:&#xD;
&#xD;
             -  Changes of extracellular volume by CMR (T1 mapping) at 2 year follow up&#xD;
&#xD;
             -  Evaluation of the degree of the resting LV diastolic function&#xD;
&#xD;
             -  Evaluation of global and regional LV strain&#xD;
&#xD;
             -  Other echo-parameters; LV mass index at baseline, 2 year follow up, reduction of&#xD;
                peak exercise E/E prime at 2 year follow up&#xD;
&#xD;
             -  Changes of quality of life using questionnaire&#xD;
&#xD;
             -  Change of peak VO2, exercise time, AT by diastolic stress echocardiography at 2&#xD;
                year follow up&#xD;
&#xD;
             -  Change in T1 baseline (myo, ms) &amp; T1 baseline (blood, ms) T1 postcontrast (myo, ms)&#xD;
                &amp; T1 baseline (blood, ms) by CMR&#xD;
&#xD;
        3. Study Methods -Study Design: This is an observational study. No treatment or&#xD;
           intervention will be assigned to the subjects. All patients will receive full standard&#xD;
           of care concomitant medication for the treatment of their cardiac condition. 20 patients&#xD;
           with genetically confirmed Anderson-Fabry disease who have a plan to start Migalastat&#xD;
           will undergo 2D strain, diastolic stress echocardiography, LV vortex flow analysis, and&#xD;
           CMR at baseline and after 2 year of treatment with Migalastat for follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2020</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of peak exercise E/E' by diastolic stress echocardiography</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of global longitudinal strain</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of LV vortex flow parameters</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of extracellular volume by CMR (T1 mapping)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the degree of the resting LV diastolic function</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of global and regional LV strain</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of LV mass index</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of reduction of peak exercise E/E prime</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of quality of life using Short Form 36</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of peak VO2 by diastolic stress echocardiography</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of exercise time by diastolic stress echocardiography</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of AT by diastolic stress echocardiography</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T1 baseline (myo, ms) &amp; T1 baseline (blood, ms) T1 postcontrast (myo, ms) &amp; T1 baseline (blood, ms) by CMR</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Fabry's disease</arm_group_label>
    <description>Fabry's disease patients who were confirmed by enzyme assay and gene study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>LV vortex flow in Echocardiography</description>
    <arm_group_label>Fabry's disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10cc blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 16 ~ 70 years with Fabry disease confirmed by enzyme assay and gene test&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 16 ~ 70 years with Fabry's disease who were confirmed by enzyme assay&#xD;
             and gene study&#xD;
&#xD;
          2. Patients who have LV hypertrophy in 2D echocardiography (end diastolic septum and&#xD;
             posterior wall thickness ≥12mm) or Patients who present with cardiac changes&#xD;
             (indicative of disease progression such as decreased global longitudinal strain on 2D&#xD;
             strain echocardiography or low native T1 mapping on cardiac MRI) even without LV wall&#xD;
             thickness of ≥12mm&#xD;
&#xD;
          3. Patients provided with the written, informed consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication for chaperone therapy (Migalastat)&#xD;
&#xD;
          2. Patients who cannot perform supine bicycle stress echocardiography, contrast&#xD;
             echocardiography or cardiac MRI&#xD;
&#xD;
          3. Hemodynamically significant valvular heart disease or arrythmias&#xD;
&#xD;
          4. History of acute myocardial infarction or congestive heart failure with reduced LV&#xD;
             ejection fraction of less than 35%&#xD;
&#xD;
          5. CVA in the prior 6 months&#xD;
&#xD;
          6. Scheduled or planned surgery in the next 6 months&#xD;
&#xD;
          7. Chronic liver cirrhosis&#xD;
&#xD;
          8. Allergy to contrast agent (Definity®, Lantheus Medical Imaging, North Billerica, MA,&#xD;
             USA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geu-Ru Hong, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geu-Ru Hong, Ph.D</last_name>
    <phone>82+2-2228-8443</phone>
    <email>grhong@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geu-Ru Hong, Ph.D</last_name>
      <phone>82+2-2228-8443</phone>
      <email>grhong@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

